Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias

Chandan Guha, Kosho Yamanouchi, Jinlan Jiang, Xia Wang, Namita Roy Chowdhury, Alfredo Santana, Lawrence J. Shapiro, Eduardo Salido, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Primary hyperoxalurias (PHs) are diseases caused by overproduction of oxalate by hepatocytes. Most patients with PHs develop nephrocalcinosis and renal failure. Combined liver-kidney transplantation is often used as a definitive treatment of PHs, but because of a large body oxalate load at the time of transplantation, the procedure is not always successful. Because all hepatocytes overproduce oxalate, partial liver replacement procedures, such as auxiliary transplantation of a liver lobe or hepatocyte transplantation are not expected to be useful in this disorder. In this paper we describe novel techniques, based on preparative hepatic irradiation and stimulation of hepatocyte mitosis, through loss of liver mass or administration of hepatic growth factor, which permit transplanted wild-type hepatocytes to massively repopulatethe liver, replacing up to 90% of the hepatocytes in recipient mouse livers. Application of this procedure in a recently developed Agxt-gene-deleted mouse model of PH1 resulted in marked amelioration of hyperoxaluria. We propose that further refinement of the different components of this procedure may permit early cell-based therapies of PHs, thereby preventing renal failure and its complications.

Original languageEnglish (US)
Pages (from-to)161-170
Number of pages10
JournalAmerican Journal of Nephrology
Volume25
Issue number2
DOIs
StatePublished - Mar 2005

Fingerprint

Primary Hyperoxaluria
Hepatocytes
Transplantation
Oxalates
Liver
Liver Transplantation
Renal Insufficiency
Therapeutics
Hyperoxaluria
Nephrocalcinosis
Cell- and Tissue-Based Therapy
Secondary Prevention
Mitosis
Kidney Transplantation
Intercellular Signaling Peptides and Proteins
Genes

Keywords

  • Fas/CD95
  • Hepatic growth factor
  • Hepatic irradiation
  • Hepatocyte transplantation
  • Primary hyperoxalurias

ASJC Scopus subject areas

  • Nephrology

Cite this

Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. / Guha, Chandan; Yamanouchi, Kosho; Jiang, Jinlan; Wang, Xia; Chowdhury, Namita Roy; Santana, Alfredo; Shapiro, Lawrence J.; Salido, Eduardo; Roy-Chowdhury, Jayanta.

In: American Journal of Nephrology, Vol. 25, No. 2, 03.2005, p. 161-170.

Research output: Contribution to journalArticle

Guha, Chandan ; Yamanouchi, Kosho ; Jiang, Jinlan ; Wang, Xia ; Chowdhury, Namita Roy ; Santana, Alfredo ; Shapiro, Lawrence J. ; Salido, Eduardo ; Roy-Chowdhury, Jayanta. / Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. In: American Journal of Nephrology. 2005 ; Vol. 25, No. 2. pp. 161-170.
@article{6f46c1a4ac3749e2a4d7d327b725691f,
title = "Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias",
abstract = "Primary hyperoxalurias (PHs) are diseases caused by overproduction of oxalate by hepatocytes. Most patients with PHs develop nephrocalcinosis and renal failure. Combined liver-kidney transplantation is often used as a definitive treatment of PHs, but because of a large body oxalate load at the time of transplantation, the procedure is not always successful. Because all hepatocytes overproduce oxalate, partial liver replacement procedures, such as auxiliary transplantation of a liver lobe or hepatocyte transplantation are not expected to be useful in this disorder. In this paper we describe novel techniques, based on preparative hepatic irradiation and stimulation of hepatocyte mitosis, through loss of liver mass or administration of hepatic growth factor, which permit transplanted wild-type hepatocytes to massively repopulatethe liver, replacing up to 90{\%} of the hepatocytes in recipient mouse livers. Application of this procedure in a recently developed Agxt-gene-deleted mouse model of PH1 resulted in marked amelioration of hyperoxaluria. We propose that further refinement of the different components of this procedure may permit early cell-based therapies of PHs, thereby preventing renal failure and its complications.",
keywords = "Fas/CD95, Hepatic growth factor, Hepatic irradiation, Hepatocyte transplantation, Primary hyperoxalurias",
author = "Chandan Guha and Kosho Yamanouchi and Jinlan Jiang and Xia Wang and Chowdhury, {Namita Roy} and Alfredo Santana and Shapiro, {Lawrence J.} and Eduardo Salido and Jayanta Roy-Chowdhury",
year = "2005",
month = "3",
doi = "10.1159/000085408",
language = "English (US)",
volume = "25",
pages = "161--170",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias

AU - Guha, Chandan

AU - Yamanouchi, Kosho

AU - Jiang, Jinlan

AU - Wang, Xia

AU - Chowdhury, Namita Roy

AU - Santana, Alfredo

AU - Shapiro, Lawrence J.

AU - Salido, Eduardo

AU - Roy-Chowdhury, Jayanta

PY - 2005/3

Y1 - 2005/3

N2 - Primary hyperoxalurias (PHs) are diseases caused by overproduction of oxalate by hepatocytes. Most patients with PHs develop nephrocalcinosis and renal failure. Combined liver-kidney transplantation is often used as a definitive treatment of PHs, but because of a large body oxalate load at the time of transplantation, the procedure is not always successful. Because all hepatocytes overproduce oxalate, partial liver replacement procedures, such as auxiliary transplantation of a liver lobe or hepatocyte transplantation are not expected to be useful in this disorder. In this paper we describe novel techniques, based on preparative hepatic irradiation and stimulation of hepatocyte mitosis, through loss of liver mass or administration of hepatic growth factor, which permit transplanted wild-type hepatocytes to massively repopulatethe liver, replacing up to 90% of the hepatocytes in recipient mouse livers. Application of this procedure in a recently developed Agxt-gene-deleted mouse model of PH1 resulted in marked amelioration of hyperoxaluria. We propose that further refinement of the different components of this procedure may permit early cell-based therapies of PHs, thereby preventing renal failure and its complications.

AB - Primary hyperoxalurias (PHs) are diseases caused by overproduction of oxalate by hepatocytes. Most patients with PHs develop nephrocalcinosis and renal failure. Combined liver-kidney transplantation is often used as a definitive treatment of PHs, but because of a large body oxalate load at the time of transplantation, the procedure is not always successful. Because all hepatocytes overproduce oxalate, partial liver replacement procedures, such as auxiliary transplantation of a liver lobe or hepatocyte transplantation are not expected to be useful in this disorder. In this paper we describe novel techniques, based on preparative hepatic irradiation and stimulation of hepatocyte mitosis, through loss of liver mass or administration of hepatic growth factor, which permit transplanted wild-type hepatocytes to massively repopulatethe liver, replacing up to 90% of the hepatocytes in recipient mouse livers. Application of this procedure in a recently developed Agxt-gene-deleted mouse model of PH1 resulted in marked amelioration of hyperoxaluria. We propose that further refinement of the different components of this procedure may permit early cell-based therapies of PHs, thereby preventing renal failure and its complications.

KW - Fas/CD95

KW - Hepatic growth factor

KW - Hepatic irradiation

KW - Hepatocyte transplantation

KW - Primary hyperoxalurias

UR - http://www.scopus.com/inward/record.url?scp=20844442634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844442634&partnerID=8YFLogxK

U2 - 10.1159/000085408

DO - 10.1159/000085408

M3 - Article

VL - 25

SP - 161

EP - 170

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -